Speculative Outlook on Unicure Buyout Prospects

18 days ago

Speaker

"Will my price target what would be your price target for cure in case of a bio here? Let's un let's let's understand this from a linguistics perspective first. What would be your price target for cure in case of a buyout conservatively? That is our question, right? Cure is not a cure for Huntington's to be clear. It's a treatment. It's a potential treatment without exactly definitive control data. So, it's speculative treatment. If a company were to be bought out, I mean, you can't, it doesn't make sense. What would your price target be? I guess what you're trying to ask is, do you think there is a drug company out there willing to pay a premium right now for Unicure stock price? I don't think that's the right way to think about it."

The speaker discusses the idea of setting a price target for Unicure in the event of a buyout. He clarifies that Unicure offers a speculative treatment for Huntington's rather than a definitive cure, emphasizing that drug companies are unlikely to pay a substantial premium without clear data. This commentary highlights the complexities behind M&A expectations and cautions investors against assuming a buyout scenario as a basis for valuation.

Related Stocks